Your browser doesn't support javascript.
Eupatin, a Flavonoid, Inhibits Coronavirus 3CL Protease and Replication.
Park, Yea-In; Kim, Jang Hoon; Lee, Siyun; Lee, Ik Soo; Park, Junsoo.
  • Park YI; Division of Biological Science and Technology, Yonsei University, Wonju 26493, Republic of Korea.
  • Kim JH; Department of Herbal Crop Research, National Institute of Horticultural & Herbal Science, RDA, Eumsung 27709, Republic of Korea.
  • Lee S; Division of Biological Science and Technology, Yonsei University, Wonju 26493, Republic of Korea.
  • Lee IS; Km Covergence Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea.
  • Park J; Division of Biological Science and Technology, Yonsei University, Wonju 26493, Republic of Korea.
Int J Mol Sci ; 24(11)2023 May 24.
Article in English | MEDLINE | ID: covidwho-20241072
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic has caused more than six million deaths worldwide since 2019. Although vaccines are available, novel variants of coronavirus are expected to appear continuously, and there is a need for a more effective remedy for coronavirus disease. In this report, we isolated eupatin from Inula japonica flowers and showed that it inhibits the coronavirus 3 chymotrypsin-like (3CL) protease as well as viral replication. We showed that eupatin treatment inhibits SARS-CoV-2 3CL-protease, and computational modeling demonstrated that it interacts with key residues of 3CL-protease. Further, the treatment decreased the number of plaques formed by human coronavirus OC43 (HCoV-OC43) infection and decreased viral protein and RNA levels in the media. These results indicate that eupatin inhibits coronavirus replication.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Year: 2023 Document Type: Article